Biontech and australia's state of victoria form strategic partnership to establish mrna research center and manufacturing facility

Melbourne , australia, october 7, 2022 — biontech se (nasdaq: bntx) today announced that it has agreed a letter of intent with the state of victoria in australia on a strategic partnership between the state and biontech to collaborate on the research and development of potential mrna-based vaccines and therapies. as part of the partnership, the parties will establish a research and innovation center in melbourne to facilitate the transition of encouraging academic research into clinical development. biontech plans to set up a clinical scale end-to-end mrna manufacturing facility based on its biontainer solution in melbourne with the aim of supporting the design, manufacture and clinical testing of product candidates. part of biontech's global network, the facility is expected to attract interest from researchers locally, regionally and globally.
BNTX Ratings Summary
BNTX Quant Ranking